Mereo BioPharma (MREO) Convertible Debt (2023)
Mereo BioPharma (MREO) reported Convertible Debt of $4.4 million for Q4 2023.
Mereo BioPharma (MREO) Convertible Debt (2023) Analysis & Trends
Mereo BioPharma (MREO) has 1 years of Convertible Debt data on file, last reported at $4.4 million in Q4 2023.
- Convertible Debt for Q4 2023 came in at $4.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $4.4 million (changed N/A YoY), and the FY2023 annual result was $4.4 million, changed N/A from the prior year.
- Convertible Debt was little changed at $4.4 million in Q4 2023 per MREO's latest filing.
- Over five years, Convertible Debt peaked at $4.4 million in Q4 2023 and troughed at $4.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mereo BioPharma | 252.49 Mn | 252.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.39 Mn |